Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SFDA To Segregate Responsibilities Of Drug Administration, Appraisal And Approval

This article was originally published in PharmAsia News

Executive Summary

According to its recently published reorganization plan, China's State FDA will spread the control of drug administration, appraisal and approval into different bureaus. For instance, a new food permission bureau will be set up to exclusively approve food, cosmetics and healthcare products, while other bureaus will manage related responsibilities. In addition, SFDA will transfer the jurisdiction of technology appraisal on drug and medical devices to its lower level institutions, the National Institute for the Control of Pharmaceutical and Biological Products, Chinese Pharmacopoeia Commission, Center for Drug Evaluation and Medical Devices Evaluation Center. SFDA will now approve and supervise healthcare products. The constant policy revision means imminent change in the industry's product brand names, R&D and classification. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts